BGC > Product Search > Elafibranor

Description :
Elafibranor is a dual PPARα/δ agonist. Elafibranor increases plasma HDL and expression of Acox1, a PPARα target gene, and decreases plasma triglycerides and total cholesterol in the liver of ApoE2-KI wild-type mice. Elafibranor is identified as a drug candidate for the treatment of cardiometabolic diseases such as diabetes, insulin resistance, dyslipidemia, and non-alcoholic fatty liver disease (NAFLD).

• Molecular Weight :384.49
• Boiling Point :569.0±50.0°C at 760 mmHg
• Melting Point :145-147°C
• Purity :≥95%

Molecular Formula :
C22H24O4S
Canonical SMILES :
CC1=CC(=CC(=C1OC(C)(C)C(=O)O)C)C=CC(=O)C2=CC=C(C=C2)SC
InChI :
InChI=1S/C22H24O4S/c1-14-12-16(13-15(2)20(14)26-22(3,4)21(24)25)6-11-19(23)17-7-9-18(27-5)10-8-17/h6-13H,1-5H3,(H,24,25)/b11-6+
InChIKey :
AFLFKFHDSCQHOL-IZZDOVSWSA-N
Solubility :
Soluble in DMSO (Slightly), Methanol (Slightly)
Appearance :
Yellow Solid
Storage : Store at -20°C
Synonyms :
Propanoic acid, 2-[2,6-dimethyl-4-[(1E)-3-[4-(methylthio)phenyl]-3-oxo-1-propen-1-yl]phenoxy]-2-methyl-; 2-[2,6-Dimethyl-4-[(1E)-3-[4-(methylthio)phenyl]-3-oxo-1-propen-1-yl]phenoxy]-2-methylpropanoic acid; (E)-1-[4-(Methylthio)phenyl]-3-[3,5-dimethyl-4-[(carboxydimethylmethyl)oxy]phenyl]prop-2-en-1-one; GFT 505; GFT-505; GFT505

More details are to be found here